MPH, MA, BA, President & CEO, California Life Sciences Association
Sara Radcliffe joined the California Life Sciences Association (CLSA) in December 2014 and serves as President and Chief Executive Officer. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: To even more effectively push towards creating benefit for broader public health, precision medicine has to reach beyond disease identification and treatment and should aim for innovative disease prevention. As a critical element on the path towards this goal, precision medicine must incorporate data from various sources including environmental factors as well as social determinants of health. Besides the actual acquisition of this data, new technologies are required to dynamically integrate and analyze such type of information. All of these aspects will be the focus of this session.